Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05544552 · ClinicalTrials.gov registry record · Phase 1
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
A Phase 1 study of Solid Tumor and Advanced Solid Tumor, sponsored by Tyra Biosciences.
- Active
- Registry status
- Phase 1
- Development phase
- 310
- Enrollment target
- 19
- Study locations
NCT05544552: Active Phase 1 study of Solid Tumor and Advanced Solid Tumor, sponsored by Tyra Biosciences.
NCT05544552 is a Phase 1 study of Solid Tumor and Advanced Solid Tumor that is active but no longer recruiting, run by Tyra Biosciences. The registered enrollment target is 310 participants, above the 220-participant average among 196 other Solid Tumor trials with a reported enrollment target (41% higher). The trial reports 19 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05544552, a Phase 1 study of Solid Tumor and Advanced Solid Tumor, is active but no longer recruiting, sponsored by Tyra Biosciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 310 participants
- Enrollment target
- 19
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-300 in cancers with FGFR3 activating gene alterations, including locally advanced/metastatic urothelial carcinoma of the bladder and urinary tract and other advanced solid tumors.
Conditions Studied
Interventions
- DRUG TYRA-300
Study Locations (19)
Other
- Institut de Cancerologie de L'Ouest (ICO) - Saint-Herblain
- Institut Claudius Regaud, IUCT-Oncopole - Toulouse
- Gustave Roussy (Institut de Cancerologie Gustave-Roussy) - Villejuif
- NEXT Barcelona - Hospital Quironsalud Barcelona - Barcelona
- Vall d'Hebron Institut d'Oncologia (VHIO) - Barcelona
- NEXT Madrid - Hospital Universitario Quironsalud Madrid - Madrid
Massachusetts
- Dana Farber Cancer Institute - Boston
- UMass Memorial Medical Center - Worchester
Washington
- Seattle Cancer Care Alliance (SCCA) - South Lake Union - Seattle
- Linear Clinical Research Limited - Nedlands
Queensland
- Tasman Oncology - Southport
- Princess Alexandra Hospital - Woolloongabba
Victoria
- Austin Health - Heidelberg
- Peter MacCallum Cancer Research Unit - Melbourne
New York
- Memorial Sloan Kettering Cancer Center (MSKCC) - New York
North Carolina
- Duke Cancer Institute (DCI) - Duke Cancer Center - Durham
Ohio
- Cleveland Clinic - Main Campus - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 310 participants |
| Start Date | 2022-11-22 |
| Est. Completion | 2027-06 |
| Phase | Phase 1 |
What the registry record for NCT05544552 still lists
NCT05544552 is an interventional study that assigns participants to a tested intervention. The registered 310 participants enrollment target is mid-sized for trials with a published cap, above the 220-participant average among 196 other Solid Tumor trials with a reported enrollment target (41% higher).
The record links to 10 conditions, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which TYRA-300 is the first listed.
NCT05544552 lists 19 locations in 10 states (Other, Massachusetts, Washington).
Frequently Asked Questions
What is clinical trial NCT05544552 about?
NCT05544552 is a clinical study titled "Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-300 in cancers with FGFR3 activating gene alterations, including locally advanced/metastatic urothelial carcinoma of the bladder and urinary tract and other advanced s...
What is the current status of trial NCT05544552?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 310 participants. The study started on 2022-11-22. Estimated completion is 2027-06.
What conditions does trial NCT05544552 study?
This clinical trial studies the following conditions: Solid Tumor, Advanced Solid Tumor, Bladder Cancer, Urothelial Carcinoma, Solid Tumor, Adult.
What interventions are being tested in trial NCT05544552?
The interventions under investigation include: TYRA-300 (DRUG).
Who is sponsoring clinical trial NCT05544552?
This trial is sponsored by Tyra Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05544552 being conducted?
This trial has 19 study locations across Massachusetts, New York, North Carolina, Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05544552's enrollment target sits among peer trials
310 21st of 196 higher than 176 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03039439 · 310 participants
Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors
- NCT04178018 · 310 participants · NA
Transvaginal Ultrasound and Photoacoustic Imaging of Ovary
- NCT04878094 · 310 participants · Phase 3
A Study of Intra-operative Imaging in Women With Ovarian Cancer
- NCT05459233 · 310 participants · NA
Valve Hemodynamic Optimization Based on Doppler-Echocardiography vs Catheterization Measurements Following ViV TAVR
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI